Rutgers-developed biomaterial drives a technology transfer story towa...( is the ideal example of industry sponso...),Health

is the ideal example of industry sponsoring research on cutting edge technology developed in academia. The brilliance and productivity of Professor Kohn and his laboratory staff will contribute substantially to the ultimate commercialization of our bioresorbable stents."

REVA President Bob Schultz added, "We undertook a careful and exhaustive search for an ideal polymer to suit our product specifications for durability, safety, uniqueness, and other critical properties in designing a next generation stent product. We worked closely with Professor Kohn and his group in selecting polymers and processes that would improve the material. They delivered beyond our expectations."

Speaking for his research team, Kohn said, "We are grateful for the funding obtained through the National Institute of Biomedical Imaging and Bioengineering. This technology transfer story is an example of how NIH-funded research can move forward rapidly to contribute to improving health through application of basic sciences."

'"/>

Contact: Barbara Ameer
admin@njbiomaterials.org
732-445-0488
Rutgers, the State University of New Jersey
23-Nov-2004

Page: 1 2
Related medicine news :

1. Desperation drives patients
2. Yale technology translates to sonic golf training tool
3. New self-help technology set to combat eating disorders
4. PENN begins clinical trial of newest technology to treat thoracic aortic aneurysms
5. Computer memory, MRI technology benefit from student research at UH
6. PENN study emphasizes need for national guidelines for assisted reproductive technology programs
7. Countrys first simplified maze using new ultrasound technology is done at Northwestern Memorial
8. Workshop in Kathmandu on space technology for sustainable development in mountain areas
9. University of Pennsylvania Health System launches life-saving eICU technology
10. Rehabilitation professionals in nationwide survey cite barriers to assistive technology transfer
11. FDA buys technology that identifies drug toxicity to heart